Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 84.20K | -264.40K | -- | 1.62M | 219.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 84.20K | -264.40K | -- | 1.62M | 219.10K |
| Cost of Revenue | 73.00K | 285.60K | 345.70K | 2.04M | 124.80K |
| Gross Profit | 11.20K | -550.00K | -345.70K | -416.30K | 94.40K |
| SG&A Expenses | 192.20K | 192.50K | 205.30K | 327.30K | 598.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 265.20K | 478.20K | 551.00K | 2.36M | 723.50K |
| Operating Income | -181.00K | -742.60K | -551.00K | -743.60K | -504.40K |
| Income Before Tax | -297.40K | -809.40K | -646.40K | -851.90K | -575.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -297.40K | -809.40K | -646.40K | -851.90K | -575.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -297.40K | -809.40K | -646.40K | -851.90K | -575.70K |
| EBIT | -181.00K | -742.60K | -551.00K | -743.60K | -504.40K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 64.94M | 60.77M | 62.76M | 62.76M | 62.47M |
| Average Diluted Shares Outstanding | 64.94M | 60.77M | 62.76M | 62.76M | 62.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
